Abstract: Lobular neoplasia (LN) is a term that encompasses both lobular carcinoma in situ and atypical lobular hyperplasia. These lesions have been shown to constitute both risk indicators and nonobligate precursors of invasive breast cancer, they are relatively uncommon, and are most often identified in specimens taken for other reasons. Their incidence has increased in the last 2 decades, and novel variants, including a pleomorphic type, have been described. Loss of E-cadherin expression is recognized as a hallmark diagnostic feature of LN and invasive lobular carcinomas, and immunohistochemical (IHC) analysis using anti-E-cadherin antibodies has been proven to be a useful method to differentiate between lobular and ductal lesions. The frequent use of E-cadherin IHC analysis in routine diagnostic histopathology, however, has resulted in confusion with regard to the actual value of IHC with antibodies against E-cadherin and other proteins of the cadherincatenin complex. This review provides an update on recent clinicopathologic and molecular data on LN and invasive lobular carcinoma and a discussion about the use and limitations of IHC with E-cadherin in diagnostic breast pathology.
preferentially, but not exclusively, interacts with cadherins of the same type (ie, homotypic interactions). Given the restrictive tissue distribution of E-cadherin and the fact that it preferentially forms complexes with other E-cadherin molecules, this adherens-type junction protein plays pivotal roles in homotypic-homophylic adhesions between epithelial cells. [1] [2] [3] [4] [5] [6] In normal mammary epithelial cells, p120 catenin is present at the cell membrane and can be identified there by immunohistochemistry (IHC). If E-cadherin is absent or nonfunctional, p120 catenin becomes upregulated and accumulates in the cytoplasm. [5] [6] [7] [8] [9] [10] Increased cytoplasmic p120 catenin activates a series of cytoplasmic Rho-GTPases resulting in increased cell motility. [9] [10] [11] IHC analysis of epithelial cells lacking E-cadherin reveals cytoplasmic rather than membrane localization of p120 catenin (Figs. 2, 3 ).
E-cadherin IHC is commonly used in diagnostic breast pathology to help distinguish ductal carcinoma in situ (DCIS) from lobular neoplasia (LN)/atypical lobular hyperplasia (ALH)/lobular carcinoma in situ (LCIS) and invasive carcinoma of no special type 12 [also known as invasive ductal carcinoma (IDC)] from invasive lobular carcinoma (ILC), in problematic cases; however, there are a number of limitations to its use, which may not be widely recognized. In fact, there are several lines of evidence (discussed below) to demonstrate that loss of E-cadherin function and/or a dysfunctional cadherincatenin complex are common denominators of ALH, LCIS, and ILC. This review presents the historical, clinicopathologic, morphologic, and molecular issues regarding LN and ILC, as well as the caveats surrounding the use of E-cadherin IHC in diagnostic breast pathology.
HISTORICAL PERSPECTIVE
Although initially described by Ewing, 13 the term lobular carcinoma is most often credited to Foote and Stewart 14 on the basis of their seminal paper describing a group of in situ carcinomas of the breast that were not recognized by pathologists at the time. These authors used the term lobular because the changes they observed were occurring exclusively in the terminal ducts and lobules of the breast.
The histologic findings described by Foote and Stewart, still used today to recognize and diagnose LCIS, include loss of cellular cohesion, the presence of intracytoplasmic vacuoles, pagetoid spread, and the multifocality of the lesion. Muir 15 also reported on a group of similar lesions that was termed intra-acinous carcinoma, but cases of ductal phenotype with extension into lobules were present among his study sample. Although Foote and Stewart's report 14 was primarily based on in situ lesions, the authors acknowledged the existence of invasive tumors that infiltrate "in a peculiar fashion which permits one, after some experience, to recognize the high probability of such origin," and the term "lobular carcinoma" was coined.
Although the term lobular was perceived by some as an indication of the microanatomic site of origin of this type of lesion (ie, that lobular carcinomas would originate in epithelial cells from the breast lobules), Foote and Stewart actually recognized that lobular lesions would not necessarily originate in the acini and could be found in "non-lobule-containing atrophic breast." This notion was further corroborated by the seminal subgross works of Wellings et al 16, 17 who documented that preinvasive lesions of the breast originated from the terminal ductlobular unit and that the terms "ductal" and "lobular" carcinoma had no specific implications with regard to the site of origin within the mammary ductal-lobular system. Despite the fact that there are no histogenetic implications for the terms "ductal" versus "lobular," there is ample evidence, as described below, that ductal and lobular lesions represent 2 distinct clinicopathologic and biological entities.
In 1978, Haagensen et al 18 retrospectively analyzed 211 examples of in situ lobular proliferations and introduced the term lobular neoplasia (LN) to encompass both ALH and LCIS. The rationale for combining these lesions into a single category was based on the observation that, in their study, the microscopic qualitative and quantitative variations in the lobular proliferation that others used for distinguishing ALH from LCIS were not found to have any value in predicting subsequent carcinoma. On follow-up, 17.1% of patients in their study were found to have developed a "frank" carcinoma. The authors recommended systematic follow-up of patients rather than the recommendation of mastectomy suggested by Foote and Stewart. 14 Since then, authorities in the field have differed on the most appropriate terminology to be used, and different classification systems have been developed.
Although some debate as to whether LCIS should be managed clinically as a risk indicator or as a precursor of invasive carcinoma, 12, [19] [20] [21] [22] there is now overwhelming evidence to demonstrate that LCIS is a nonobligate pre- cursor of breast cancer, including the coexistence of these lesions, which share cytologic features, loss of E-cadherin, and genetic alterations. 12, [22] [23] [24] [25] [26] LN and ILC also share some genetic similarities with some lesions of the lowgrade ductal neoplasia pathway, including flat epithelial atypia (FEA), atypical ductal hyperplasia, low-grade DCIS, low-grade IDCs, and tubular carcinomas. 22, 25, 27 Thus, LN and ILC, along with the low-grade ductal lesions noted above, are currently considered to be members of a "low-grade pathway" of breast neoplasia, in which the uniqueness of the lobular pathway is defined by a dysfunctional E-cadherin/catenin complex, often due to E-cadherin loss. 12, [22] [23] [24] Given the difficulties in estimating the true prevalence of ALH and LCIS (see below), the rate of progression of these lesions to invasive breast cancer has yet to be defined.
CINICOPATHOLOGIC ISSUES
The incidence of LCIS and ILC has increased over the last 3 decades, 28-30 from 0.90/100,000 to 3.19/ 100,000 person-years in North American and European populations. 23 A more pronounced increase was noted among postmenopausal women, predominantly among those 50 to 59 years of age (11.47/100,000 person-years). The incidence of IDCs also increased during the same period but not to the same extent as that of ILCs. This disproportionate increase in lobular lesions has been attributed to the use of postmenopausal hormone replacement therapy, the introduction of mammography screening programs, the implementation of magnetic resonance imaging (MRI) in breast cancer patient management, and more accurate histologic diagnoses with the use of E-cadherin IHC. 30, 31 In particular, LN is frequently found concurrently with columnar cell lesions and FEA, which are being detected increasingly in biopsies performed because of mammographically detected microcalcifications. 12, 22 LN is a microscopic lesion that does not form a palpable tumor and does not result in a grossly apparent alteration. 14, 18 Thus, in breast biopsies removed for a palpable abnormality, LN is always an incidental finding. 32, 33 Retrospective analyses report that most cases of LCIS are classified mammographically as BI-RADS 3 or 4. [32] [33] [34] [35] LCIS is also commonly discovered incidentally in breast tissue removed for lesions that are prone to bear microcalcifications, such as columnar cell change, FEA, and sclerosing adenosis. The fact that LCIS is multifocal and often nondetectable clinically is one of the reasons why planning subsequent management has proven problematic and contentious. Modern imaging techniques, including MRI, have emerged as potential complementary approaches for the follow-up of patients with LCIS. 36 Although there are no distinct mammographic features associated with LCIS, recent studies have reported some examples of LCIS that are associated with mammographic microcalcifications. Microcalcifications have been reported in association with classic LCIS in as many as 42% of cases. [32] [33] [34] [35] Some authors have highlighted the importance of identifying the subpopulation of LCIS with neoplastic cell-related calcifications because of a potential higher risk to be associated with upstaging on follow-up excision biopsy. 32, 33 LCIS of the classic type is reported to be associated with small punctate calcifications, whereas pleomorphic LCIS (PLCIS, discussed below) presents with large, clustered and pleomorphic calcifications related to the presence of central (comedotype) necrosis akin to those seen in high-grade DCIS. 37, 38 The diagnostic distinction between ductal and lobular lesions is important in several circumstances for therapeutic reasons. With regard to the distinction between DCIS and classic LCIS, DCIS is managed either with complete local excision, with or without radiation therapy, or with mastectomy. Evaluation of the microscopic margin status is required in cases of DCIS treated with breast-conserving therapy. In contrast, classic LCIS is typically managed by observation alone, risk reduction using selective estrogen receptor modulators, or less commonly, bilateral mastectomy. Microscopic margin status is not a concern in cases of classic LCIS, but clear margin status should be considered for patients with a diagnosis of PLCIS (see below). A management strategy of DCIS would be appropriate for cases of mixed DCIS and LCIS. An ambiguous diagnosis of DCIS/LCIS should be a very rare event if E-cadherin is properly used with p120 catenin or b-catenin, but it may be prudent to approach such cases using a multidisciplinary approach and to err on the side of complete excision if a definitive diagnosis cannot be rendered.
The distinction of IDCs from ILCs also has clinical implications. At some institutions, a diagnosis of ILC on core biopsy may prompt MRI of the breast to determine the patient suitability for breast-conserving therapy. 39, 40 In addition, ILCs, which are generally hormone receptor rich, tend to have a poorer response to neoadjuvant chemotherapy compared with IDCs. 39, 40 Finally, the pattern of metastasis is known to be different for ILC and IDC, with the former being more likely to spread to unusual sites including the gastrointestinal tract, gynecologic organs, and meninges. 41 
MORPHOLOGY-MICROSCOPIC PATHOLOGY
LN distorts the terminal duct-lobular unit. In the classic form of LCIS, at least 50% of the normally coapted elongated acini within a lobule are distorted into a rounded shape because of the filling of the acini by a monomorphic population of round, ovoid, or polygonal cells that display a thin rim of cytoplasm and a high nuclear to cytoplasmic ratio. 12, 14, 18 As a result, the rounded acini appear to be distended by the monomorphic cells. The nuclei are uniform and the chromatin fine and evenly dispersed. Nucleoli are inconspicuous. A characteristic cytologic feature is the presence of intracytoplasmic lumina, which may be large enough to produce signet ring cells. The cells are usually loosely cohesive to frankly dyshesive, are regularly spaced, and fill and distend the involved acini. Mitotic figures are rare and necrosis is usually not seen.
The definition of ALH is the involvement of the lobule to a lesser extent than that of LCIS by the same population of monomorphic cells. Lobular involvement and distension should be defined as 8 or more cells present in the cross-sectional diameter of an acinus and that the number of acini involved in cases of ALH should account for less than half of the whole terminal ductlobular unit. 12, 29, 42, 43 The appearance of ALH will therefore be more variable, but the same abnormal monomorphic cells will be within the acinar spaces (Fig. 2C) .
The neoplastic cells of LN often extend along adjacent ducts in a pagetoid manner, with the LN cells dispersed between the intact overlying epithelium and the underlying basement membrane. 12, 14, 18 The cells comprising classic LCIS as described above, with low-grade, uniform nuclei, are also referred to as "type A" cells. 18 An architecturally similar lesion, containing cells with larger, more (moderately) variable nuclei with variably prominent nucleoli and, often, more abundant cytoplasm, has been referred to as "type B" LCIS. Both type A and type B LCIS are considered together as "classic" LCIS, and the clinical significance of the distinction between type A and type B cells remains to be determined.
Diagnostic tribulations may ensue when LN colonizes preexisting breast lesions. The presence of LN in sclerosing lesions such as sclerosing adenosis, radial scars, or complex sclerosing lesions may produce patterns mimicking invasive carcinoma. Papillomas, fibroadenomas, usual ductal hyperplasia, and collagenous spherulosis may also be populated by LCIS cells, leading to challenging diagnostic patterns. 19 These diagnostic tribulations can be laid to rest by demonstrating the lack of E-cadherin and cytoplasmic p120 catenin in the areas of question.
PLCIS is architecturally similar to classic LCIS, yet is composed of markedly pleomorphic high-grade cells with nuclear features similar to those of grade 3 DCIS cells. The cells are substantially larger than type A or type B cells of classic LCIS, in the range of Z4 times the size of a lymphocyte (see below). PLCIS is often seen with pleomorphic ILC, but may also be seen as an isolated, in situ lesion. 44, 45 Nuclei are often eccentrically placed, have nuclear membrane irregularities, and display conspicuous nucleoli. In some cases, the cells comprising PLCIS exhibit abundant, eosinophilic cytoplasm imparting an apocrine appearance 44, 46 and/or large intracytoplasmic vacuoles imparting a signet ring cell appearance. HER2 overexpression and gene amplification can be found and are reported more frequently in PLCIS with apocrine differentiation. 46, 47 Massive distension of involved spaces with foci of central, comedo-type necrosis and calcification is common. As noted above, PLCIS is often encountered in conjunction with cytologically similar pleomorphic ILC, and, occasionally, areas of transition between the 2 can be observed. In cases of PLCIS, areas of bona fide classic LCIS are also commonly found. 44, 45 Sneige et al 45 emphasized that type B cells have nuclei that are up to twice the size of a lymphocyte (type A cells are 1 to 1.5 times larger), whereas PLCIS nuclei are typically 4 times larger with more prominent nucleoli. By definition, PLCIS cells lack membrane Ecadherin and show cytoplasmic p120 catenin. The combination of cellular features, necrosis, and calcification can lead to difficulty in distinguishing PLCIS from highgrade DCIS. It should be noted, however, that lack of Ecadherin, although required, is not sufficient to render a high-grade in situ lesion a PLCIS, given that a subset of high-grade triple-negative DCIS may show diminished Ecadherin expression. Therefore, a diagnosis of PLCIS requires that the lesions displays both histologic (ie, highgrade, discohesive cells) and IHC features consistent with those of a PLCIS, including the lack of high-molecular weight keratins (ie, cytokeratins 5/6, 14, and 17), which are often present in high-grade DCIS.
In most cases, the distinction of in situ and invasive lobular lesions from ductal lesions is straightforward on hematoxylin and eosin-stained sections. Some cases, however, create diagnostic challenges. In such cases, IHC for E-cadherin and other proteins in the cadherin-catenin complex is a useful adjunct in arriving at the correct diagnosis, albeit with several important caveats, as discussed below.
E-CADHERIN IHC
LN and ILCs are characterized by the loss of membranous E-cadherin expression, as well as the loss of expression of other membrane-located cell adhesion molecules, such as b-catenin and p120 catenin. [48] [49] [50] These changes are characteristic of LN and are useful for distinction from ductal lesions. 12, 19, 22, 48, 49, [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] Another characteristic immunophenotypic feature of lobular lesions is the presence of cytoplasmic expression of p120 catenin. 48, 49, 59 As mentioned above, p120 catenin, normally bound to the intracytoplasmic domain of E-cadherin, becomes upregulated and visible in the cytoplasmic compartment by IHC when E-cadherin is lost through mutation or silencing. 9 This contrasts with cell membrane expression of p120 catenin in normal mammary epithelial cells and in ductal lesions. Cytoplasmic expression of p120 catenin is thus a positive IHC marker for lobular lesions, and, in subtle and difficult cases, it is a useful adjunct to histology and E-cadherin IHC. 48, 49 It must be emphasized that E-cadherin membranous positivity does not preclude the diagnosis of a lobular lesion. Some LCIS and ILCs may display aberrant E-cadherin membranous expression 58, 59, 61 (Fig. 4) . The prevalence of this phenomenon in LCIS has not been well documented, but in 1 recent study up to 15% of ILCs exhibited membranous E-cadherin expression. 59 E-cadherin expression, when present in LCIS and ILCs, is aberrant, not in the form of a continuous membrane staining pattern seen in normal epithelial cells or the cells of in situ and invasive ductal lesions, but in the form of fragmented, focal, or beaded expression patterns. However, complete, weak membranous E-cadherin staining may be seen in LCIS or ILC. 58 In these types of cases, immunostaining for b-catenin may be useful; loss of b-catenin expression indicates that, although E-cadherin is present on the cell membrane, it is dysfunctional and not associating normally with other molecules in the cadherin-catenin complex. 50, 58, 59 Another very useful marker is p120 catenin, which is expressed on the cell membranes in in situ and invasive ductal lesions, but found in the cytoplasm of LN and ILC. In cases of lobular lesions with E-cadherin membrane expression, cytoplasmic expression of catenin p120 is indicative that the E-cadherin complex is dysfunctional. 48, 49, 58, 59 Indeed, this can be well demonstrated by a double immunostain for E-cadherin and p120 catenin (Fig. 4D) .
We suggest that the use of E-cadherin as an ancillary diagnostic marker should follow some basic guidelines: (1) E-cadherin IHC should be avoided for in situ and invasive breast lesions that clearly exhibit lobular morphology on hematoxylin and eosin-stained sections. Given that aberrant expression of E-cadherin can occur in bona fide lobular lesions, the diagnosis of a lobular lesion is not negated in a lesion that has classic lobular histologic features but also shows Ecadherin membranous expression. In contrast, cases with the appropriate histologic features that are unequivocally E-cadherin negative should be classified as lobular in nature. The use of p120 catenin, along with E-cadherin, is encouraged to resolve discordance between morphology and the E-cadherin pattern of staining. (2) Some cases defy categorization as definitively lobular or definitively ductal even after IHC for E-cadherin and the other cell adhesion proteins is performed. The molecular basis for the existence of mixed lesions lies in the similarities in the repertoire of genetic aberrations found in lobular and low-grade ductal lesions (see below). It is also plausible that in some lesions, individual neoplastic cells can have an indeterminate or hybrid phenotype (ie, the cells are neither fully lobular nor fully ductal). In cases of in situ or invasive carcinoma that have equivocal histologic features and remain indeterminate on IHC analysis for E-cadherin, a diagnosis of in situ or invasive carcinoma with ductal and lobular features is justifiable. (3) Some truly lobular lesions may display heterogeneity of staining for E-cadherin. In such cases, expression of E-cadherin may range from completely absent to weak, fragmented membrane staining, to weak or even strong circumferential membrane staining, to cytoplasmic staining. In cases in which IHC for E-cadherin fails to permit definitive categorization of a lesion as ductal or lobular, p120 catenin or b-catenin may be of value to ascertain whether the E-cadherin is dysfunctional. This could provide confirmation of a lobular phenotype despite the presence of E-cadherin membranous expression.
Molecular Aspects of E-Cadherin Inactivation
E-cadherin inactivation or downregulation occurs through a combination of genetic, epigenetic, and transcriptional mechanisms. Loss of chromosome 16q is usually accompanied by truncating mutations or gene promoter methylation leading to biallelic inactivation of the gene and loss of protein expression. 22, 52, 55 Gene mutations have been identified in ALH (7%), LCIS (100%), and ILC (27% to 65%) but are rare in IDC. 16, 39, 54 In fact, recent massively parallel sequencing studies of invasive breast cancers have confirmed a statistically significant association between lobular carcinomas and CDH1 gene mutations 62, 63 ; however, not all lobular carcinomas harbor CDH1 gene mutations, 52, 55, 62 and up to 2% of IDCs may display CDH1 somatic mutations. 62, 63 Identical CDH1 truncating mutations have been found in LCIS and associated ILC supporting the role of LCIS as a precursor for ILC. 21 In one study, the frequency of CDH1 mutations in pure ALH was reported to be lower than that detected in pure LCIS. 64 This was unexpected given that E-cadherin expression is already downregulated at the stage of ALH. This observation may have resulted from the challenges of extracting DNA from samples with relatively small numbers of ALH cells, which may have been admixed with residual luminal and myoepithelial cells.
In addition to deletions, mutations, and methylation of the CDH1 gene, there are considerable data on the transcriptional regulation of E-cadherin by a number of different transcription factors. This has recently been specifically described in lobular lesions by activation of the TGFb pathway, SNAIL and SLUG upregulation, and by ZEB1 expression. 65 There is also evidence to suggest that in the progression from LN to ILC there is a stepwise decrease of the mRNA and proteins of the E-cadherin and catenin families from LCIS to ILC, and upregulation of TWIST and SNAIL. 66 In fact, transcriptional downregulation of E-cadherin may be an alternative mechanism for loss of E-cadherin expression in ILCs lacking CDH1 gene mutations and promoter methylation.
Evidence for E-cadherin inactivation being directly related to the lobular phenotype has been demonstrated in a mouse tumor model with conditional mutation of E-cadherin and epithelial-specific knockout of p53. 67 Mammary tumors and metastases that developed had a strong morphologic resemblance to human lobular carcinoma. 67, 68 However, this model had some significant differences from human lobular carcinomas, in particular lack of ER and PR expression, presence of TP53 gene mutations, and positivity for basal keratins, which are features not typically associated with human ALH, LCIS, and ILC. In fact, given that p53 was inactivated in this model, tumors these animals develop would have histologic and molecular features that more recapitulate the cardinal features of pleomorphic ILC. 68 
Genome-wide Genomics of Lobular Carcinoma
Comparative genomic hybridization (CGH), single nucleotide polymorphism arrays and loss of heterozygosity approaches have been used to study LN and ILC. 22, 25, 40, 47, [69] [70] [71] [72] [73] [74] [75] [76] These analyses have not only confirmed the clonal nature of LN 20, 25 but also its role as a precursor in the development of ILC. 13, 22, 25, 47, [69] [70] [71] [72] [73] [74] [75] LCIS and ALH are genetically similar, 69, 74 with both lesions harboring recurrent losses of material from 16p, 16q, 17p, and 22q and gain of material from 6q, which are alterations that are also identified in ILCs. 22, 25, [69] [70] [71] [72] [73] [74] [75] Other alterations occur less frequently, and this heterogeneity may account for the variable biological and clinical nature of lobular proliferations. For example, loss of 11q was found in B50% of ILCs, and genomic amplifications at 8p12-p11.2 and 11q13 were present in B10% to 30% of classic ILCs. 22, 25, [69] [70] [71] [72] [73] [74] [75] These alterations have also been reported in LCIS suggesting that they are early genetic events in the development of these tumors. The target genes affected may vary from case to case as, for example, the amplifications are complex and variable; however, fibroblast growth factor receptor 1 (FGFR1; 8p12-p11.2) and cyclin D1 (CCND1, 11q13) overexpression is frequently associated with these amplifications. [77] [78] [79] In one study, pure ALH harbored a surprisingly high level of genetic instability compared with pure LCIS 76 and lobular lesions from other studies. 22, [72] [73] [74] This was interpreted as a mechanism by which ALH cells acquire high-level genetic instability and die rather than progress to LCIS and ILC. 76 An alternative explanation is the technical challenges in obtaining optimal quality DNA samples for microarray-based CGH from ALH samples.
PLCIS and pleomorphic ILC are genetically related entities, highlighting the precursor role of PLCIS in the development of pleomorphic ILC 46, 72, 80 akin to the relationship between classic LCIS and ILC. They have similar genomic profiles to classic LCIS and ILC including gain of 1q and 16p and loss of 11q and 16q. However, they also harbor amplification of genomic loci involving oncogenes associated with an aggressive phenotype, such as MYC (8q24) and HER2 (17q12). 46, 72, 80 Chen et al 46 directly compared the genomic profiles of 21 cases of PLCIS (8 apocrine and 13 nonapocrine subtypes) with those of 20 classic LCIS, all without a concurrent or prior ipsilateral invasive cancer. Both groups were characterized by similar genetic alterations, the most prevalent being 1q gain (75% in pleomorphic vs. 69% in classic) and 16q loss (85% in pleomorphic vs. 76% in classic). Overall, no significant differences in the extent of genetic changes were detected between the 2 groups, but some focal genetic changes were more frequent in the pleomorphic lesions, including amplification of CCND1 (14% vs. 5%) and HER2 (10% vs. 0%). Interestingly, more overt differences were found when comparing classic and nonapocrine PLCIS with the apocrine PLCIS, which had significantly more genomic alterations. It is noteworthy that amplifications of 17q and 11q and gain of 16p were present only in the latter. However, when comparing the profiles of apocrine PLCIS with those of high-grade DCIS, the latter displayed far more genomic alterations. Those findings corroborate to the notion that classic LCIS and PLCIS are closely related entities distinct from DCIS and suggest that the apocrine subtype of PLCIS is a more genetically advanced lesion. Differences in immunoprofiles are consistent with this notion, as apocrine PLCIS are mostly (80%) ER-negative and harbor HER2 overexpression and gene amplification in about a third of cases. Given the reported differences in the biomarker profiles and molecular features of apocrine and nonapocrine PLCIS, further studies are warranted to define the histologic criteria for and the clinical significance of these 2 variants of PLCIS.
Data from an independent group also support the notion that well-developed in situ lobular lesions defined as "necrotic lobular intraepithelial neoplasia/LIN3" follow a similar molecular evolutionary pathway as classic LCIS, with frequent 1q gain and 16q loss, but also harbor additional numerical chromosomal alterations 81 with focal high-level amplifications, usually present in invasive cancers. The authors then proposed that "necrotic LIN3 represents a lesion on the verge of invasion." Nevertheless, a significant number of LCIS progress to an invasive phenotype without having necrosis superimposed. Moreover, it should be noted that this study included cases with concurrent invasive carcinoma and a mixture of lesions with classic and pleomorphic cytologic features, limiting, therefore, its clinical significance.
Clearly, loss of 16q plays a crucial and very early role in the pathogenesis of lobular and low-grade ductal neoplasia contributing to the loss of E-cadherin in LN, as described above. It is unclear whether loss of other tumor suppressor genes mapping to this region play a role in the biology of lobular carcinomas, and the genes from this region that are important in the development of lowgrade ductal carcinomas remain elusive. 12, 22 In fact, it is possible that some genes mapping to 16q and recurrently targeted by heterozygous deletions in low-grade ductal and lobular carcinomas are affected by haploinsufficiency. 82 Further studies to define the driver genes of 16q deletions in ductal lesions and to determine whether additional tumor suppressor genes mapping to 16q play a role in LN and ILCs are warranted.
Whole-genome Gene Expression Profiling of Lobular Carcinoma
ILCs are significantly different from IDCs at the transcriptomic level. 75, 79, [83] [84] [85] [86] [87] [88] [89] Several studies have directly compared the profiles of these 2 morphologic entities, and all concluded that the 2 constitute distinct molecular entities, differing not only by the downregulation of E-cadherin but also by the differential expression of other genes predominantly related to cell adhesion, cell motility, and epithelial-mesenchymal transition. It should be noted, however, that a small subset of ILCs have been shown to express normal mRNA levels of CDH1, whereas a subset of IDCs have CDH1 mRNA expression levels similar to those found in bona fide ILCs. 62 Despite similar conclusions, the overlap between the lists of genes differentially expressed from all studies is minimal. 87 In fact, downregulation of CDH1 in ILCs is the only consistent finding in all publications. This should not come as a surprise given that this is a common limitation of whole-genome microarray-based gene expression analysis. Moreover, the results of most studies are confounded by the fact that ILCs more frequently express ER and are of low histologic grade and luminal molecular subtype compared with IDCs, which are features that are associated with distinct genome-wide transcriptomic patterns. Weigelt et al 87 controlled for these factors by matching ILCs and IDCs by histologic grade and molecular subtype. Using this unbiased approach, the authors demonstrated that ILCs cluster separately from IDCs according to the histologic type, rather than the histologic grade or molecular subtype. Supervised analysis revealed that 5.8% of the transcriptionally regulated genes were significantly differentially expressed. ILCs displayed downregulation of E-cadherin and of many genes related to actin cytoskeleton remodeling, protein ubiquitin, DNA repair, cell adhesion, TGFb signaling as well as upregulation of transcription factors/immediate-early genes, lipid/prostaglandin biosynthesis genes, and cell migration-associated genes. Interestingly, it has been suggested that low-grade classic ILCs may have a more overt luminal phenotype as compared with low-grade IDCs, as they display higher expression of ER-responsive genes. Similar observations were described when comparing classic ILCs with molecular subtype-matched tubular carcinomas. 90 In fact, direct comparisons between classic ILCs and molecular subtype-matched low-grade IDCs and tubular carcinomas revealed that, although these 3 distinct morphologic tumors share similar IHC and genetic profiles and may form a low-grade breast neoplasia family, they are not identical at the molecular level. 87, 90 Subtle differences between these entities do exist and may partly explain the better prognosis of the patients with tubular carcinomas.
A similar approach has been undertaken by Gruel et al, 75 who analyzed by array CGH and microarraybased gene expression profiling a series of 62 ER-positive invasive tumors, of which 21 were ILCs and 41 were IDCs of similar histologic grades, and confirmed that the differences between ILCs and IDCs are independent of ERstatus and histologic grade. Genes differentially expressed between ILCs and IDCs displayed similar functions, being involved in cell adhesion, cell communication and trafficking, extracellular matrix interaction pathways, or cell motility. This striking global transcriptomic pattern of ILCs provides a molecular basis not only for its typical dyscohesiveness and infiltrative morphology but also for the metastatic pattern. In addition, some genes involved in chromatin maintenance and RNA metabolism were downregulated in ILCs, which is a feature that may partly explain their low proliferation rates.
The gene expression profiles of classic ILCs have also been compared with those of pleomorphic ILCs. 87 Supervised analysis revealed that of 7095 significantly regulated transcripts only 7 were differentially expressed between the 2 subtypes of ILCs, indicating that classic and pleomorphic ILCs are remarkably similar at the transcriptomic level. These findings, albeit hypothesisgenerating because of the small sample size, provide another level of evidence that pleomorphic ILC should be indeed viewed as an ILC variant and not as a high-grade IDC that has lost E-cadherin expression.
CONCLUSIONS
LN and ILCs constitute a distinctive family of neoplastic proliferations of the breast characterized by specific clinical, morphologic, and molecular features. As a group, all of the morphologic variants of lobular neoplastic proliferations are underpinned by similar genetic and transcriptomic features, having the loss of E-cadherin function as one of its defining molecular events. Importantly, it is critical for pathologists to understand the usefulness as well as the limitations of the E-cadherin IHC in breast pathology to avoid diagnostic pitfalls.
